A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants

NCT ID: NCT07254728

Last Updated: 2025-11-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 76 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-27
• Study Completion Date: 2024-12-13

Brief Summary

The primary objective of this study is to evaluate the safety and tolerability of an oral bivalent GI.1/GII.4 norovirus vaccine administration in healthy lactating female participants and to assess the short-term immunogenicity of oral bivalent GI.1/GII.4 norovirus vaccine administration in healthy lactating female participants and its association with the immunogenicity response in breastmilk.

Conditions

Norovirus Infections

Keywords

Healthy participants; VXA-G1.1-NN; VXA-G2.4-NS

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Bivalent GII.4/GI.1 Medium Dose Vaccine

Participants will receive a medium dose of bivalent VXA-G1.1-NN and VXA-GII.4-NS as an oral tablet on Day 1.

Group Type: EXPERIMENTAL

VXA-G1.1-NN

Intervention Type: BIOLOGICAL

Oral tablets.

VXA-G2.4-NS

Intervention Type: BIOLOGICAL

Oral tablets.

Bivalent GII.4/GI.1 High Dose Vaccine

Participants will receive a high dose of bivalent VXA-G1.1-NN and VXA-GII.4-NS as an oral tablet on Day 1.

Group Type: EXPERIMENTAL

VXA-G1.1-NN

Intervention Type: BIOLOGICAL

Oral tablets.

VXA-G2.4-NS

Intervention Type: BIOLOGICAL

Oral tablets.

Placebo

Participants will receive matching placebo orally on Day 1.

Group Type: PLACEBO_COMPARATOR

Placebo Tablets

Intervention Type: BIOLOGICAL

Oral tablets.

Interventions

VXA-G1.1-NN

Oral tablets.

Intervention Type: BIOLOGICAL

VXA-G2.4-NS

Oral tablets.

Intervention Type: BIOLOGICAL

Placebo Tablets

Oral tablets.

Intervention Type: BIOLOGICAL

Other Intervention Names

GI.1; GII.4

Eligibility Criteria

Inclusion Criteria

1. Lactating females aged ≥ 18 years at the time of enrolment and their breastfed infants aged >30 days to 11 months of age at the time of the participants' study drug administration.

2. In stable and good general health, without significant medical illness, based on medical history, physical examination (including vital signs), and clinical judgment of the investigator.

3. Lactating females willing and able to provide informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.

4. Lactating females who are willing to provide consent for their breastfed infant.

5. Negative pregnancy tests at screening and prior to dose on Day 1.

6. Available for all planned visits and tele-health appointments, and ability to comply with all study-related evaluations (including but not limited to having the ability and willingness to swallow multiple small enteric-coated tablets per study dose, express/pump breastmilk, and collect infant stool samples).

7. Plan to continue breastfeeding as the main source of the infant's nutrition for at least 1 month (longer is preferred with goal of 6 months post dose if possible) from the time of study drug administration. Exclusive breastfeeding is acceptable but not necessary.

8. The nursing infant is the product of a singleton pregnancy AND does not have any of the following:

1. Any abnormality that may interfere with breastfeeding or milk absorption

2. Active infection (may be included if the infection resolves and the participant is re-assessed during the screening period)

3. Infant has any other medical condition or abnormality that, in the opinion of the investigator, could compromise the infant's appropriate inclusion in this study including interference with the interpretation of study results (such as malabsorption)

4. One or more documented brief resolved unexplained events (BRUEs)

5. Extreme prematurity (infants who were born at less than 28 weeks gestation)

6. 30 days of age or less at the participant's study drug administration OR greater than 11 months of age at the participant's study drug administration

7. Prior hospitalization that is not exclusively for hyperbilirubinemia requiring phototherapy

8. Any genetic/metabolic disease

9. Any chronic illness requiring long term medication

9. Participants must be willing to use a highly effective form of contraception for 30 days prior to vaccination and until 60 days after the vaccination. Acceptable forms are oral, implantable, intrauterine, transdermal, intravaginal, injectable, double barrier or abstinence (participants using diaphragms must also use condom). The form of contraception must be approved by the investigator.

Exclusion Criteria

1. Presence of a fever ≥ 38.0°C measured orally at baseline, on Day 1 prior to vaccination. (Assessment may be repeated once during screening period).

2. Acute disease within 72 hours prior to vaccination, defined as the presence of a moderate or severe illness (as determined by the Investigator through medical history and physical exam). (Assessment may be repeated once during screening period).

3. Participants who have received antipyretic/analgesic medications within 24 hours prior to the intended vaccine administration.

4. Positive human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) tests at the screening visit.

5. History of hypersensitivity or allergic reaction to any component of the investigational vaccine, including but not limited to fish gelatin.

6. History of serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain.

7. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including the institution of new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months of screening and reconfirmed at baseline.

8. History of significant pregnancy-related complications during this pregnancy, including but not limited to pre-eclampsia, eclampsia, or gestational diabetes unless a full resolution is documented.

9. Cancer, or treatment for cancer, within the past 3 years (excluding fully treated and resolved basal cell carcinoma or squamous cell carcinoma).

10. Presence of immunosuppression or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus type 1 or 2.

11. History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine. Such conditions may include but are not limited to:

a. Any history of:

i. Malignancy

ii. Malabsorption

iii. Pancreatobiliary disorders

iv. Inflammatory bowel disease

v. Irritable bowel disease

vi. Hiatal hernia

vii. Surgical resection

b. History of diagnosis or treatment in past 5 years of:

i. Esophageal or gastric motility disorder

ii. Gastroesophageal reflux disease (GERD) - Will allow for participants with a history of pregnancy-related GERD if fully resolved for >3 months and no other history of GERD diagnosis

iii. Peptic ulcer

iv. Cholecystectomy

12. Any condition that resulted in the absence or removal of the spleen.

13. History of any form of angioedema.

14. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic.

15. History of GI bleeding including hematochezia (blood in stool) or melena (black stool).

16. Any significant hospitalization within the last year which in the opinion of the investigator or sponsor could interfere with study participation.

17. Any of the following history or conditions that may lead to a higher risk of clotting events and/or thrombocytopenia:

1. Family or personal history of bleeding or thrombosis

2. History of heparin-related thrombotic events, and/or receiving heparin treatments

3. History of autoimmune or inflammatory disease

4. Presence of any of the following conditions known to increase the risk of thrombosis within 6 months prior to screening:

i. Recent surgery other than fully healed cesarean delivery or excision/ biopsy of cutaneous lesions

ii. Immobility (confined to bed or wheelchair for 3 or more successive days)

iii. Head trauma with loss of consciousness or documented brain injury

iv. Receipt of anticoagulants for prophylaxis of thrombosis

v. Recent clinically significant infection including hospitalization for COVID-19 related illness

18. Any other condition that, in the clinical judgment of the investigator, would jeopardize the safety or rights of a participant taking in the study, would render the participant unable to comply with the protocol, or would interfere with the evaluation of the study endpoints.

19. Receipt of a licensed vaccine (including any COVID-19 vaccines under Emergency Use Authorization) within 14 days prior to study drug dose or planned administration during the study active period.

20. Use of antibiotics, proton pump inhibitors, H2 blockers, or antacids within 7 days prior to study drug administration or planned use during the active study period.

21. Use of medications known to affect the immune function (including but not limited to systemic corticosteroids, leukotriene modifiers, and Janus kinase [JAK] inhibitors) within 2 weeks before study drug administration or planned use during the active study period.

22. Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug administration or planned use during the active study period.

23. Donation or receipt of blood or blood products within 30 days prior to study drug administration or planned donation during the active study period.

24. Participating in any clinical trial with another investigational product within 30 days prior to the first trial visit or intend to participate in another clinical trial at any time during the conduct of this trial.

25. Are first-degree relatives of individuals involved in trial conduct.

26. Positive urine drug screen for drugs of abuse at screening.

27. Positive alcohol test at screening or baseline.

28. History of drug, alcohol, or chemical abuse within 1 year of screening.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Vaxart

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Vaxart, Inc.

Locations

WITS RHI Research Centre

Hillbrow, , South Africa

Progress Clinical Research Unit

Honeydew, , South Africa

Newtown Clinical Research Centre

Johannesburg, , South Africa

Trident Clinical

Kimberley, , South Africa

FCRN Clinical Trials Centre (Pty) Ltd

Vereeniging, , South Africa

Countries

South Africa

Other Identifiers

VXA-NVV-108

Identifier Type: -

Identifier Source: org_study_id